ABVC BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 15, 2023 at 08:01 am EST
Share
ABVC BioPharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.015884 million compared to USD 0.042269 million a year ago. Net loss was USD 3.32 million compared to USD 3.7 million a year ago. Basic loss per share from continuing operations was USD 0.82 compared to USD 1.14 a year ago. Diluted loss per share from continuing operations was USD 0.82 compared to USD 1.14 a year ago.
For the nine months, sales was USD 0.150265 million compared to USD 0.380789 million a year ago. Net loss was USD 7.4 million compared to USD 11.56 million a year ago. Basic loss per share from continuing operations was USD 2.08 compared to USD 3.71 a year ago. Diluted loss per share from continuing operations was USD 2.08 compared to USD 3.71 a year ago.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
ABVC BIOPHARMA, INC. 
